Tarsus Pharmaceuticals Inc (TARS)

Mar 12, 2025, 9:49 PM EDT - 4 weeks ago

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Mar 12, 2025, 4:12 PM EDT - 4 weeks ago

Tarsus Announces Proposed $100.0 Million Public Offering

Mar 11, 2025, 12:36 PM EDT - 4 weeks ago

Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Mar 6, 2025, 5:00 PM EST - 5 weeks ago

Tarsus to Participate in Upcoming Investor Conference

Feb 25, 2025, 6:01 PM EST - 6 weeks ago

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 5:00 PM EST - 7 weeks ago

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Jan 30, 2025, 5:00 PM EST - 2 months ago

Tarsus to Participate in Upcoming Investor Conferences

Jan 13, 2025, 8:30 AM EST - 3 months ago

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Dec 15, 2024, 2:00 PM EST - 4 months ago

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

SWTX

Nov 13, 2024, 10:23 PM EST - 5 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 8:30 AM EST - 5 months ago

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Nov 6, 2024, 4:30 PM EST - 5 months ago

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Nov 5, 2024, 8:30 AM EST - 5 months ago

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Oct 17, 2024, 8:30 AM EDT - 6 months ago

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Sep 25, 2024, 5:00 PM EDT - 7 months ago

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

Sep 20, 2024, 3:17 PM EDT - 7 months ago

Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations

Aug 28, 2024, 5:00 PM EDT - 8 months ago

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

Aug 20, 2024, 4:56 PM EDT - 8 months ago

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Aug 10, 2024, 1:50 PM EDT - 8 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript

Jul 29, 2024, 4:30 PM EDT - 9 months ago

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

May 9, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

May 8, 2024, 9:45 PM EDT - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:05 PM EDT - 1 year ago

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

May 1, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

Mar 7, 2024, 8:03 PM EST - 1 year ago

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tarsus to Participate at Upcoming Investor Conferences

Mar 5, 2024, 8:30 AM EST - 1 year ago

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Mar 1, 2024, 12:07 AM EST - 1 year ago

Tarsus Announces Pricing of $100.0 Million Public Offering

Feb 27, 2024, 12:09 PM EST - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 6:00 AM EST - 1 year ago

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

Feb 22, 2024, 8:00 AM EST - 1 year ago

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

Feb 20, 2024, 5:00 PM EST - 1 year ago

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

Jan 31, 2024, 5:00 PM EST - 1 year ago

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

Dec 11, 2023, 8:00 AM EST - 1 year ago

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

Dec 5, 2023, 12:00 PM EST - 1 year ago

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

AGNC CROX DPZ FHI GRPN GRVY GTN

Dec 4, 2023, 12:09 PM EST - 1 year ago

Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway

Nov 10, 2023, 6:59 PM EST - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:05 PM EST - 1 year ago

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Nov 7, 2023, 7:02 AM EST - 1 year ago

Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape

Nov 1, 2023, 6:35 PM EDT - 1 year ago

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

Sep 4, 2023, 8:36 AM EDT - 1 year ago

Tarsus Pharmaceuticals: Worthy Of A Small Bet

Aug 30, 2023, 4:30 PM EDT - 1 year ago

Tarsus to Present at Upcoming Investor Conferences

Aug 24, 2023, 9:00 AM EDT - 1 year ago

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

Aug 1, 2023, 10:30 PM EDT - 1 year ago

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

Jul 31, 2023, 4:29 PM EDT - 1 year ago

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

Jul 25, 2023, 5:56 PM EDT - 1 year ago

Tarsus Pharma: Despite Dropping After FDA Approval, 2 Catalysts Still Remain

Jul 25, 2023, 7:00 AM EDT - 1 year ago

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis